Harvard Bioscience, Inc. (HBIO)

Harvard Bioscience Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	94.14	112.25	113.34	118.9	102.1
Revenue Growth (YoY)	-16.14%	-0.96%	-4.68%	16.46%	-12.12%
Cost of Revenue	39.33	45.86	51.05	51.25	44.06
Gross Profit	54.81	66.39	62.29	67.65	58.04
Selling, General & Admin	43.52	46.61	49.03	47.32	41.39
Research & Development	10.41	11.76	12.33	10.8	8.69
Other Operating Expenses	0.35	-	-	-	-
Operating Expenses	59.53	63.9	67.48	63.96	55.79
Operating Income	-4.72	2.5	-5.19	3.69	2.25
Interest Expense	-3.21	-3.59	-2.55	-1.54	-4.83
Currency Exchange Gain (Loss)	-	-	-	-	-0.5
Other Non Operating Income (Expenses)	-0.84	-0.44	0.72	-1.02	-0.31
EBT Excluding Unusual Items	-8.77	-1.53	-7.02	1.14	-3.38
Merger & Restructuring Charges	-0.84	-0.39	-2.39	-1.28	-2.03
Gain (Loss) on Sale of Investments	-1.59	-0.63	-	-	-
Legal Settlements	-	-	0.23	-	-
Other Unusual Items	-0.47	-	-	-	-1.88
Pretax Income	-11.67	-2.56	-9.18	-0.14	-7.29
Income Tax Expense	0.74	0.86	0.34	0.15	0.52
Earnings From Continuing Operations	-12.41	-3.42	-9.52	-0.29	-7.81
Net Income	-12.41	-3.42	-9.52	-0.29	-7.81
Net Income to Common	-12.41	-3.42	-9.52	-0.29	-7.81
Shares Outstanding (Basic)	44	42	41	40	39
Shares Outstanding (Diluted)	44	42	41	40	39
Shares Change (YoY)	2.64%	2.43%	2.65%	4.41%	2.19%
EPS (Basic)	-0.28	-0.08	-0.23	-0.01	-0.20
EPS (Diluted)	-0.28	-0.08	-0.23	-0.01	-0.20
Free Cash Flow	-1.2	12.24	-0.44	0.07	8.18
Free Cash Flow Per Share	-0.03	0.29	-0.01	0.00	0.21
Gross Margin	58.22%	59.15%	54.96%	56.90%	56.85%
Operating Margin	-5.01%	2.22%	-4.58%	3.10%	2.21%
Profit Margin	-13.18%	-3.04%	-8.40%	-0.24%	-7.65%
Free Cash Flow Margin	-1.28%	10.90%	-0.39%	0.06%	8.01%
EBITDA	2.44	9.49	2.38	11.31	9.89
EBITDA Margin	2.59%	8.46%	2.10%	9.51%	9.68%
D&A For EBITDA	7.16	7	7.58	7.62	7.63
EBIT	-4.72	2.5	-5.19	3.69	2.25
EBIT Margin	-5.01%	2.22%	-4.58%	3.10%	2.21%

Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q